Impact of antiretroviral therapy in mortality of Chilean HIV (+) patients: A case-control study;Impacto de la terapia anti retroviral en la mortalidad de pacientes VIH (+) chilenos: Estudio caso-control (MORTAR)

Revista Medica de Chile

Volumn 128, Issue 8, 2000, Pages 839-845

  Wolff R, Marcelo ^a,b   Bustamante M, Claudia ^a   Bidart H, Teresa ^a   Dabanch P, Jeannette ^a   Diomedi P, Alexis ^a   Northland A, Rebeca ^a  

^a HOSPITAL SAN BORJA ARRIARÁN   (Chile)

^b Arriaran Foundation   (Chile)

Author keywords

HIV antibodies; HIV seropositivity; Retroviridae infections; Reverse transcriptase inhibitors

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; AIDS RELATED COMPLEX; ARTICLE; CASE CONTROL STUDY; CHILE; DRUG ADMINISTRATION; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MIDDLE AGED; MORBIDITY; MORTALITY; RETROSPECTIVE STUDY; RISK; STATISTICS;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; CASE-CONTROL STUDIES; CHILE; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; MORBIDITY; ODDS RATIO; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0034241216     PISSN: 00349887     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. FISCHL MA, RICHMAN DD, GRIECO MH, GOTTLIEB MS, VOLBERDING PA, LASKIN OL, ET AL. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind, placebo-controlled trial. N Engl J Med, 1987; 317: 185-91.
2. VOLBERDING PA, LAGAKOS SW, KOCH MA, PETINELLI C, MYERS MVV, BOOTH BK, ET AL. Zidovudine in asymptomatic human immunodeficiency virus infection: a controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. N Engl J Med, 1990; 322: 941-9.
3. FISCHL MA, RICHMAN DD, HANSEN N, COLLIER AC, CAREY JP, HARDY WD, ET AL. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection: a double-blind, placebo-controlled trial. Ann Intern Med, 1990; 112: 727-37.
4. FISCHL MA, OLSON RM, FOLLANSBEE SE, LALEZARI JP, HENRY DH, FROME PT, ET AL. Zalcitabine compared with zidovudine in patients with advanced HIV-1 infection who received previous zidovudine therapy. Ann Intern Med, 1993; 118: 782-9.
5. LAMBERT JS, SEIDLIN M, REICHMAN RC, PLANK CS, LAVERTY M, MORSE GD, ET AL. 2′,3′-Dideoxyinosine (ddl) in patients with the acquired immunodeficiency syndrome or AIDS-related complex: a Phase 1 trial. N Engl J Med, 1990; 322: 1333-40.
6. ERON JJ, BENOIT SL, JEMSEK S, MACARTHUR RD, SANTANA J, QUINN JB, ET AL. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200-500 CD4 + cells per cubic millimeters. N Engl J Med, 1995; 333: 1662-9.
7. HAMMER SM, KATZENSTEIN DA, HUGHES MD, GUNDACKER H, SCHOOLEY RT, HAUBRICHT RH, ET AL. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell count from 200 to 500 per cubic millimeter. N Engl J Med, 1996; 335: 1081-90.
8. SARAVOLATZ LD, WINSLOW DL, COLLINS G, HODGES JS, PETINELLI C, STEIN DS, ET AL. Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. N Engl J Med, 1996; 335: 1099-106.
9. DELTA COORDINATING COMMITEE. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet, 1996; 348: 293-1.
10. MOUTON Y, ALFANDARI S, VALETTE M, CARTIER F, DELLAMONICA P, HUMBERT G, ET AL. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. AIDS, 1997; 11: 101-5.
11. HOGG RS, O'SHAUGHNESSY MV, GATARIC N, YIP B, CRAIB K, SCHECHTER MT ET AL. Decline in deaths from AIDS due to new antiretrovirals. Lancet, 1997; 349: 1294.
12. TORRES RA, BARR M. Impact of combination therapy for HIV infection on inpatient census. N Engl J Med, 1997; 336: 1531-2.
13. PALELLA FJ JR, DELANEY KM, MOORMAN AC, LOVELESS MO, FUHRER J, SATTEN GA ET AL. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med, 1998; 338: 853-60.
14. HOGG RS, YIP B, KULLY C, GRAIB KJ, O'SHAUGHNESSY MV, SCHECHTER MT, MONTANER JS. Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens. CMAJ, 1999:160: 659-69.
15. HOGG RS, WEBER AE, CRAIB KJ, ANIS AH, O'SHAUGHNESSY MV, SCHECHTER MT, MONTANER J. One world, one hope: the cost of providing antiretroviral therapy to all nations. AIDS, 1998; 12: 2203-9.
16. MONTANER JS, HOGG RS, WEBER AE, ANIS AH, O'SHAUGHNESSY MV, SCHECHTER MJ. The cost of triple drug anti-HIV therapy in the Americas. JAMA, 1998; 279: 1283-4.
17. FLOYD K, GILKS C. Cost and financing aspects of providing anti retroviral therapy: A background paper. En World Bank Homepage: http://www. wordlbank.org/aidsecon/arv/Floyd/Index.Htm 19 Dic. 1999.
18. HAMMER SM, SQUIRES KE, HUGHES MD, GRIMES JM, DEMETER LM, CURRIER JS ET AL. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med, 1997; 337: 725-33.
19. VITTINGHOFF E, SCHEER S, O'MALLEY P, COLFAX G, HOLMBERG SD, BUCHBINDER SP. Combination antiretroviral therapy and recent declines in AIDS incidence and mortality. J Infect Dis, 1999; 179: 717-20.
20. HOGG RS, HEATH KV, YIP B, CRAIB KJ, O'SHAUGHNESSY MV, SCHECHTER MT, MONTANER JS. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA, 1998; 179: 450-4.
21. HO DD. Viral counts count in HIV infection. Science, 1996; 272: 1124-5.
22. MELLORS JW, MUÑOZ A, GIORGI JV, MAHGOLICK JB, TASSONI CJ, GUPTA P ET AL. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med, 1997; 126: 946-54.
23. MELLORS JW, RINALDO CR JR, GUPTA P, WHITE RM, TODD JA, KINGSLEY, LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996; 272: 1107-70.
24. O'BRIEN WA, HARTIGAN PM, DAAR ES, SIMBERKOFF MS, HAMILTON JD. Changes in plasma HIV RNA levels and CD4-lymphocyte counts predict both response to antiretroviral and therapeutic failure. Ann Intern Med, 1997; 126: 939-45.
25. REGGY A, WONG T, CHIASSON M, SIMONDS R, LOO V, HEFFESS J. Protease inhibitors and declining AIDS rate in New York City (NYC). Presentado en: V Conference on Retrovirus and Opportunistic Infections, Chicago, Febrero 2-6, 1998, trabajo (abstract) # LB 7.
26. CDC. Case-control study of HIV seroconversion in health-care workers after percutaneus exposure to HIV-infected blood. France, United Kingdom and United States, January 1988 - August 1994. MMWR, 1995; 44: 929-33.
27. BRODT HR, KAMPS BS, GUTE P, KNUPP B, STASZEWSKI S, HELM EB. Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy. AIDS, 1997; 11: 1731-8.
28. EGGER M, HIRSCHEL B, FRANCIOLI P, SUDRE P, WIRZ M, FLEPP M ET AL. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. BMJ, 1997; 315: 1194-9.
29. WOLFF M, NORTHLAND R, SEGOVIA J, BELTRÁN C, VALDÉS M, ALBORNOZ M ET AL. Características clinicas e historia natural de la infección por virus de inmunodeficiencia humana. Rev Méd Chile, 1995; 123: 61-73.